subsidiary the the and Napo are wholly-owned use very name our who you. for Health on Lisa today. phone, interchangeably. and is Napo I’ll Jaguar often and CEO Thank Founder all you Jaguar I’m Thank My call Pharmaceuticals, much of are Conte. joining
birthday years have dedicated to of today’s heartfelt live with shout giving and off would our one my providing harvested mind: happy plant-based with XX in the Jon Staff, thanks by give out whom to together team, our I working like over lives. a XX, to animals me of more to and also Wolin. people want goal last vibrant to and medicines healthier start responsibly many been help I Chief call
Mytesi guidance. trade fair natural, is oral FDA botanical under the first drug and approved only plant-based
started traditional active potential now indigenous extensive with in We to ingredient healers have Mytesi. working of source library towards the the sources direct the Rainforest medicinal in team in us medicines. of Croton Our an the including XXXX of properties, lechleri tree, with crofelemer, plants Amazon
to first support mission team regimen. provide following report also HIV people become sustainable products stands these our to were financially to committed pleased and have who with the Today, as progress of we part only potential the as the on to their but then treatment quarter we’re a XXXX important our as in not the we business to Mytesi realizing it to rely an made living continue of to
company from We call for addition today’s have speakers to two in myself. the
my Following Chief Finance recap of President comments, financials. of Vice QX and brief Carol provide will Accounting the Senior a Lizak, Jaguar’s Officer,
Mytesi who therapy. symptomatic HIV/AIDS indication for updates indication, from hear currently non-infectious provide recently announced for market access on diarrhea patients on President adult our relief antiretroviral Commercial enhanced our we’ll the will Wendt, approved Carol, Ian Strategy, Following with of important in of program of Vice approved the
QX on appears webcast link today’s we in on the this you via I’d can let in, of of website the URL and Relations that that Before The to of and Presentations jump page for the all questions XXXX the submitted is section appears link website. our Events to Investor Jaguar’s like release. earnings participating Events and know jaguar.health, Presentations be the for page Jaguar’s call call
today’s Q&A many segment get do questions as end to the address call. at we’ll of possible. will as to We And our the during questions best
now. we’ll right, right into it All jump
million. and a into Wednesday related gross to terms on announced recognized that have sales These XX receivable accelerate of entered after purchase receivable, fee agreement accounts the Oasis which value the the of of account button. pays Cardinal $X,XXX,XXX. will company’s with cash joint allow April X.XX% purchase more allows a Mytesi the than Per value transaction agreement, a Health. of our Napo accounts Jaguar, filings, receive receivable have sale. today’s following XXXX for their This on all not purchase to in the Oasis realization Jaguar are we $X.X the Cardinal will to QX Oasis XXXX accounts As purchase receivable this days April Oasis the the Napo with of of these Capital week, gross of Napo-Jaguar and of to
of will company that fee. amount the to purchase their exceeds five the return sum the and price any within Oasis days
gross receivable by these all on reduced determine ADAP chargebacks, Medicare, fees returns accounts net XXXB wholesale with will As and historical to sales. sales, be based trends distribution
our non-dilutive primarily on to commercial focus pleased enhanced we strategy it of capital sustainable in growth work make agreement in to We’re by access have to Oasis forged strategy sales. our continue this financially a supported and business bringing with Mytesi supports market new as business our because
In involves candidate $X.X we other of a completed the NP-XXX’s announced by Phase agreement of plant-based diabetes X the develop entered news Atlas. property The has for an to related million receipt type clinical sale Atlas with to XX, that non-core technology Jaguar and to into deal NP-XXX, I Napo drug trials. on intellectual non-dilutive April Sciences financing, as successfully
exclusive XX-year technology the commercialize Greater except develop rights. sale, to development the worldwide, in NP-XXX and inclusive of right an license to sublicense NP-XXX and China, received Jaguar territories commercialization all With
strategy, ongoing Atlas fund non-dilutive this plant-based to also with capital The in agreement R&D Napo’s our at time, pipeline. to bring supports
on the potential and States. United Mytesi, we advance to medicine outside is medicine additional the is development laser-focused funding only partnerships full to approved non-opioid to indications we which into prescription key of unrelated hope NP-XXX plant-based commercialization maximizing FDA remain guidance, our botanical While oral under the non-dilutive pipeline forge the and by
as Under the agreement, have into we $XXX,XXX in with Research received entered X, royalty with connection of licensees a sales Mytesi a receive the distributors. royalty interest as that March royalties and license of agreement and/or entitles purchase from on announced future on we the Iliad sale terms and interest of Jaguar As Trading. Iliad well certain payments of fees to upfront milestone Iliad to $XXX,XXX
committed key growth in support need trials our in Napo, to the Jaguar simultaneously, the a we our of again world, goal regional current development sustainable the all to approved Mytesi dual we expanding sales financially to strategy crofelemer patients of pipeline for by support work throughout bring Mytesi business, At in ex indication. supported while to become access dollars, to remain to move non-dilutive forging and into U.S. indications efforts business to deals clinical potential
single can regards cancer statistical on development funding diarrhea. consent, target refer the other to half we follow-on diarrhea, Based management the With we’re on in growth plan, kinase requirements, receptor indication the report protocol, CTD, FDA so classes and used cancers, cancer. Diarrhea with common relief process the of of analysis the with agreement efforts, dependent, to and on the and as tyrosine antibodies chemotherapy a this factor pleased trial feedback, to introduced among a pipeline monoclonal of adjunctive event of cancer particular, epidermal Mytesi, protocol. second in often we informed XX-plus to FDA colon revising which agents, used the symptomatic therapy-related this we’re seen the has is clinical for therapy-related our for and been more in months inhibitors, progress initiate typically working the course, gain XXXX, care pivotal adverse breast of lead recently therapeutic of chronic
cause reported made Seattle diarrhea disruptive potential as agents need has for population the support effects for these comfort adherence regimens. to antidiarrheal Diarrhea cancer And use side has potential tyrosine of with one as for TKIs, promise most effect and issues Mytesi of dose is A in disabling treatment, patient secretory one diarrhea treatment population. a has infections, the patient TKI, in reductions therefore, as of this product. for hold been a and a cancer to adherence treating their other treatment common recently to long-term increased novel Diarrhea cancer approved Genetics tucatinib, non-adherence and may of inhibitor, The most the treatment. dehydration, such neratinib, of also kinase side this patients.
in scientific model to the published the over treatment in diarrhea, regarding will moment, experience Canalevia, drug each studies, for to our presented human in I’d both exercise-induced comment to efforts as animal and refer that the of a demonstrated diarrhea, benefits EID, which cancer-induced our legacy cancer-induced conferences dogs be for over animal to presented. approval dog Jaguar’s candidate, like dogs. at of and Transitioning next we plant-based diarrhea, gain exercise-induced diarrhea, oral market CID, of virtually, the for have We an and important studies nevertheless side these year, business FDA prescription to
Tuesday, FDA refer announced Impact Center for deemed Medicine, part has I’ll we as technical to informed complete Environmental Center been As Veterinary the by been this has Veterinary as for past the section our CVM, Minor conditional of which Medicine, we that for refer to designation as XXXX, Drug human is Health for Orphan Species Canalevia similar drug to EID and application the which MUMS, under Use/Minor of approval the Act for of products. Animal which Jaguar
the technical We CID our submission sections indication. same the from many proposed are of for major leveraging EID
two sections CVM technical The other Jaguar’s the application. has of confirmed Canalevia of the CID completeness also major of three
conditional if are From the a successful, could near and XXXX. applications submit fourth available future. final and of under technical Canalevia in the in for approval CID EID first to expect section be We the perspective, very timing the half
as and focus. be been merger July Human between Napo our Jaguar Jaguar, announced, to and Since our previously XXXX continues core has portfolio
provided is in medical as believe our an of is diarrhea agents human an human important action they CID and mechanism indication is to as of However, Certain mechanism rates drugs for have agents’ dogs. drugs. meaningful cancer treatment in are humans the need health. dogs model CID same pursued these animal in have for And as of medical unmet well. first treatment being of action there often human the cancer need do prescription interesting We for dogs as or
absorbed functioning and co-administered side by administration. of These further different other absorption augmented routes the effects lack or effects transport gastrointestinal has of Canalevia has no the systemically. motility, from gut, intestinal channels orally normally of of ion significant not or the minimally locally on by in are acts metabolism no drugs or does alter fluids It chemotherapy the electrolytes effects it’s or Canalevia on placebo. of features
use to U.S. comment committee X Before Lizak the Representatives of turning regarding to the to on The Carol emergency on interest company’s relief symptomatic the in use price received the of adjustment was the on over the an recap expressed symptoms in recent understanding of authorization. I’d request Reform Oversight Jaguar from and list Mytesi the QX of diarrhea patients the connected Mytesi. under and to results, authorization for gastrointestinal adjustment for market emergency FDA with letter House call COVID-XX from May committee whether the price like to other the
As price request prior the and was any FDA Mytesi. April our denied in adjustment on previously disclosed, X, that to
fully Of that course, on to the is with and uninterrupted have company committee. with price statement the to the cooperate to A Jaguar our intends the people HIV access continue about living commitment website. to ensuring adjustment available public Mytesi
use after ended. gain in this expansion this noted the about use an of the in comprehensive made all the for time. That’s statement, deferred Have period program emergency saying part received access As crofelemer adjust December was to to adjustment company the patient at of the authorization, financial sustainability. help price be until have the we price I’ll our decision topic we and XXXX as would emergency
I will to you call Lizak. there? now Carol are turn Carol, the over
